REMARKS

Original claims 1-8 have been amended, claims 9-11 have been cancelled, and claims 12–36 have been added. Specifically, the term "neutralizing" has been deleted from claims 1, 3, 5 and 6; "wherein" has been substituted for "in which" in claim 2; "comprising" has been substituted for "incorporating" in claim 4; and the American English forms of the word "immunize" have been substituted for English "immunise" in claims 7 and 8. Claims 9 and 10 have been cancelled due to their election and prosecution in related patent application serial no. 08/451,197. Claims 1-8 and 12-27 represent the previously unelected claims of Groups I and II from related patent application serial no. 08/451,197. Claims 28-36 are directed to HCMV monospecific polyclonal antisera raised to (i) gH-based polypeptides of the amino acid sequence of Figure 5, (ii) a gH polypeptide from a HCMV strain functionally equivalent to AD169, or the polypeptide of (i) or (ii) lacking the C-terminal anchor sequence. Support for the claim amendments and new claims can be found in the original claims as well as throughout the specification at, *inter alia*, page 8, line 18; page 12, lines 19 through page 14, line 15; page 23, line 7-25; and page 27, line 13 through page 31, line 11. Thus, no new matter has been introduced to the application in the new or amended claims.

The amendment to the specification merely adds priority information for this **divisional** application and, therefore, does not introduce new matter.

Applicant respectfully request entry of the above amendments prior to examination of this application. If the Examiner is of the opinion that a telephone conference would expedite prosecution of the application, the Examiner is encouraged to contact Applicant's undersigned representative.

Date: June 20, 2003

Registration No. 37,142

McDonnell Boehnen Hulbert & Berghoff

Respectfully submitted,

Telephone: 312-913-0001 Facsimile: 312-913-0002

300 South Wacker Drive Chicago, IL 60606